{"clinical_study": {"@rank": "57", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04313322"}, "id_info": {"org_study_id": "COVID-19", "nct_id": "NCT04313322"}, "brief_title": "Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells", "official_title": "Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells", "sponsors": {"lead_sponsor": {"agency": "Stem Cells Arabia", "agency_class": "Other"}}, "source": "Stem Cells Arabia", "oversight_info": {"is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal\n      stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2\n      infection, and showing symptoms of COVID-19."}, "detailed_description": {"textblock": "COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a\n      high transmission rate and is spreading at very high rates. causing a worldwide pandemic.\n      Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three\n      IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each\n      other.\n\n      Patients will be followed up for a period of three weeks to assess the severity of the\n      condition and measure the viral titers."}, "overall_status": "Recruiting", "start_date": {"@type": "Anticipated", "#text": "March 16, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "September 30, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "June 30, 2020"}, "phase": "Phase 1", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"intervention_model": "Single Group Assignment", "intervention_model_description": "Patients positively diagnosed with COVID-19", "primary_purpose": "Treatment", "masking": "None (Open Label)", "masking_description": "None. This is a direct study for the potential effects of WJ-MSCs on COVID-19 outcome."}, "primary_outcome": [{"measure": "Clinical outcome", "time_frame": "3 weeks", "description": "Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea."}, {"measure": "CT Scan", "time_frame": "3 weeks", "description": "Side effects measured by Chest Readiograph"}, {"measure": "RT-PCR results", "time_frame": "3 weeks", "description": "Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative"}], "secondary_outcome": {"measure": "RT-PCR results", "time_frame": "8 weeks", "description": "Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative"}, "number_of_arms": "1", "enrollment": {"@type": "Anticipated", "#text": "5"}, "condition": "Use of Stem Cells for COVID-19 Treatment", "arm_group": {"arm_group_label": "WJ-MSCs", "arm_group_type": "Experimental", "description": "WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.\nWJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."}, "intervention": {"intervention_type": "Biological", "intervention_name": "WJ-MSCs", "description": "WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.\nWJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.", "arm_group_label": "WJ-MSCs"}, "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n        COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.\n\n        Exclusion Criteria:\n\n          -  Participants in other clinical trials\n\n          -  patients with malignant tumors\n\n          -  pregnant and lactating women\n\n          -  co-infection with other infectious viruses or bacteria\n\n          -  History of several allergies\n\n          -  Patients with history of pulmonary embolism\n\n          -  any liver or kidney diseases\n\n          -  HIV positive patients\n\n          -  Considered by researchers to be not suitable to participate in this clinical trial\n\n          -  Chronic heart failure with ejection fraction less than 30%."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers"}, "overall_contact": {"last_name": "Adeeb M AlZoubi, Ph.D.", "phone": "+962795337575", "email": "adeebalzoubi@stemcellsarabia.net"}, "overall_contact_backup": {"last_name": "Ahmad Y AlGhadi, M.Sc.", "phone": "+962796624217", "email": "ahmed.alghadi@stemcellsarabia.net"}, "location": {"facility": {"name": "Stem Cells Arabia", "address": {"city": "Amman", "zip": "11953", "country": "Jordan"}}, "status": "Recruiting", "contact": {"last_name": "Adeeb M Alzoubi, Ph.D.", "phone": "+962795337575", "email": "adeebalzoubi@stemcellsarabia.net"}, "contact_backup": {"last_name": "Ahmad AlGhadi, M.Sc.", "phone": "+962796624217", "email": "ahmed.alghadi@stemcellsarabia.net"}, "investigator": [{"last_name": "Ahmad Y AlGhadi, M.Sc.", "role": "Sub-Investigator"}, {"last_name": "Sumaya H Aldajah, M.Sc.", "role": "Sub-Investigator"}, {"last_name": "Marwa E Tapponi, Pharm.D.", "role": "Sub-Investigator"}, {"last_name": "Sameh N AlBakheet, B.Sc.", "role": "Sub-Investigator"}, {"last_name": "Mahasen Zalloum, B.Sc.", "role": "Sub-Investigator"}]}, "location_countries": {"country": "Jordan"}, "verification_date": "March 2020", "study_first_submitted": "March 15, 2020", "study_first_submitted_qc": "March 15, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 18, 2020"}, "last_update_submitted": "March 15, 2020", "last_update_submitted_qc": "March 15, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 18, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Stem Cells Arabia", "investigator_full_name": "Adeeb Al Zoubi", "investigator_title": "President, Chief Scientific Officer"}, "keyword": "Stem Cells, COVID-19, SARS CoV2, WJ MSCs, Immunomodulation,", "patient_data": {"sharing_ipd": "No"}}}